KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

TY - JOUR

T1 - KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

AU - Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group

AU - Rovin, Brad H.

AU - Adler, Sharon G.

AU - Barratt, Jonathan

AU - Bridoux, Frank

AU - Burdge, Kelly A.

AU - Chan, Tak Mao

AU - Cook, H. Terence

AU - Fervenza, Fernando C.

AU - Gibson, Keisha L.

AU - Glassock, Richard J.

AU - Jayne, David R.W.

AU - Jha, Vivekanand

AU - Liew, Adrian

AU - Liu, Zhi Hong

AU - Mejía-Vilet, Juan Manuel

AU - Nester, Carla M.

AU - Radhakrishnan, Jai

AU - Rave, Elizabeth M.

AU - Reich, Heather N.

AU - Ronco, Pierre

AU - Sanders, Jan Stephan F.

AU - Sethi, Sanjeev

AU - Suzuki, Yusuke

AU - Tang, Sydney C.W.

AU - Tesar, Vladimir

AU - Vivarelli, Marina

AU - Wetzels, Jack F.M.

AU - Floege, Jürgen

N1 - Funding Information: BHR reports consultancy for AstraZeneca/MedImmune, Aurinia, Biogen Idec, Bristol Myers Squibb, Calliditas, ChemoCentryx, EMD Serono, Genentech/Hoffmann-La Roche, Omeros, Janssen, Lupus Foundation of America, MorphoSys, Novartis, Pfizer, RILITE Foundation∗, and Travere (formerly Retrophin); grant/research support from Lupus Clinical Investigators Network∗ and the National Institutes of Health∗ Funding Information: Dr. Liu has devoted herself to patient care, research, and medical education. Her primary interest is in the field of kidney disease, with a special interest in glomerulonephritis, diabetic nephropathy, and kidney replacement therapy. She has published 650 articles, edited 5 books on kidney disease, and contributed chapters to textbooks on nephrology. She is the chief scientist of the National Basic Research Program of China (973 Program) and was honored with the National Science and Technology Progress Award of China. Funding Information: J-SFS reports grant/research support from Chiesi, Dutch Kidney Society, The Netherlands Organisation for Health Research and Development, and Novartis. Funding Information: PR reports consultancy for Alexion, Amicus, Idorsia, and MorphoSys; grant/research support from Alexion∗ and Amgen∗; providing manuscript preparation for UpToDate; receiving travel expenses from the ASN, the French Society of Nephrology, and Sanofi-Genzyme. Funding Information: HNR reports consultancy for Calliditas, Omeros, Pfizer, Retrophin; and the UHN GN Fellowship is supported by the Louise Fast Foundation; conducting clinical trials for Alnylam, Calliditas, ChemoCentryx, Omeros, and Pfizer; and speaker fees from Gilead Pharmaceuticals and Omeros. Funding Information: Dr. Reich directs the glomerulonephritis program at Toronto General Hospital, Toronto, Ontario, Canada. This rich program spans clinical care of patients with glomerulonephritis, contribution to clinical trials, and translational research. Her research program objective is to identify clinical and molecular markers of progressive glomerular diseases and to identify and evaluate novel therapeutic targets to improve outcomes of patients with glomerulonephritis. She has contributed to over 95 publications, and her work has been consistently supported by peer-reviewed awards from agencies including the Kidney Foundation of Canada and the Canadian Institutes of Health Research. She enjoys training future leaders in glomerulonephritis care and research, and she was the co-director of the annual educational pre-course in glomerulonephritis for the ASN.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85115008490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115008490&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2021.05.021

DO - 10.1016/j.kint.2021.05.021

M3 - Article

C2 - 34556256

AN - SCOPUS:85115008490

SN - 0085-2538

VL - 100

SP - S1-S276

JO - Kidney international

JF - Kidney international

IS - 4

ER -